Comparison 2. Withdrawals at 6 months ( Infliximab/MTX versus Placebo/MTX).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Total	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 MTX and Infliximab 3mg/kg q 8 weeks vs MTX(PBO)	1	174	Risk Ratio (M‐H, Fixed, 95% CI)	0.48 [0.28, 0.82]
1.2 MTX and Infliximab 3mg/kg q 4 weeks versus MTX(PBO)	2	203	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.14, 0.49]
1.3 MTX and Infliximab 10mg/kg q 8 weeks versus MTX(PBO)	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.12, 0.52]
1.4 MTX and infliximab 10mg/kg q 4 weeks versus MTX(PBO)	2	197	Risk Ratio (M‐H, Fixed, 95% CI)	0.37 [0.22, 0.64]
1.5 All Infliximab(ATTRACT)	1	428	Risk Ratio (M‐H, Fixed, 95% CI)	0.36 [0.25, 0.54]
2 Lack of Efficacy	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 MTX and infliximab 3mg/kg q 8 weeks versus MTX(PBO)	1	174	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.26, 0.99]
2.2 MTX and infliximab 3mg/kg q 4 weeks versus MTX(PBO)	2	203	Risk Ratio (M‐H, Fixed, 95% CI)	0.21 [0.10, 0.48]
2.3 MTX and infliximab 10 mg/kg q 8 weeks versus MTX(PBO)	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.23 [0.09, 0.58]
2.4 MTX and infliximab 10 mg/kg q 4 weeks versus MTX(PBO)	2	197	Risk Ratio (M‐H, Fixed, 95% CI)	0.21 [0.09, 0.49]
2.5 All Infliximab(ATTRACT)	1	428	Risk Ratio (M‐H, Fixed, 95% CI)	0.32 [0.19, 0.53]
3 Adverse Events	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 MTX and infliximab 3mg/kg q 8 weeks versus MTX(PBO)	1	174	Risk Ratio (M‐H, Fixed, 95% CI)	0.44 [0.12, 1.64]
3.2 MTX and infliximab 3mg/kg q 4 weeks versus MTX(PBO)	2	203	Risk Ratio (M‐H, Fixed, 95% CI)	0.58 [0.18, 1.93]
3.3 MTX and infliximab 10mg/kg q 8 weeks versus MTX(PBO)	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.43 [0.12, 1.62]
3.4 MTX and infliximab 10mg/kg q 4 weeks versus MTX(PBO)	2	197	Risk Ratio (M‐H, Fixed, 95% CI)	1.07 [0.40, 2.86]
4 Other	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 MTX and Infliximab 3 mg/kg q 8 weeks versus MTX(PBO)	1	174	Risk Ratio (M‐H, Fixed, 95% CI)	0.34 [0.04, 3.22]
4.2 MTX and Infliximab 3mg/kg q 4 weeks versus MTX(PBO)	2	203	Risk Ratio (M‐H, Fixed, 95% CI)	0.15 [0.01, 2.79]
4.3 MTX and Infliximab 10mg/kg q 8 weeks versus MTX(PBO)	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.01, 2.76]
4.4 MTX and Infliximab 10mg/kg q 4 weeks versus MTX(PBO)	2	197	Risk Ratio (M‐H, Fixed, 95% CI)	0.36 [0.04, 3.41]